Cancer Vaccines: The Perspective of the Cancer Immunology Branch, NCI
- 1 August 1993
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 690 (1) , 322-330
- https://doi.org/10.1111/j.1749-6632.1993.tb44020.x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Interleukin-7 mediates the generation and expansion of murine allosensitized and antitumor CTLCellular Immunology, 1992
- Tumor AntigensAnnual Review of Immunology, 1992
- Interleukin 7 induces CD4+ T cell-dependent tumor rejection.The Journal of Experimental Medicine, 1991
- Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4Science, 1991
- Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity.Proceedings of the National Academy of Sciences, 1991
- Protection of mice against tumor growth by immunization with an oncogene-encoded growth factor.Proceedings of the National Academy of Sciences, 1990
- A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.Proceedings of the National Academy of Sciences, 1990
- Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor responseCell, 1990
- Murine interleukin-4 displays potent anti-tumor activity in vivoCell, 1989
- The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity.The Journal of Experimental Medicine, 1988